TY  - JOUR
AU  - Zweig, Jeffrey
AU  - Wakelee, Heather
PY  - 2017
TI  - METLung: a disappointing result in a challenging patient population
JF  - Translational Cancer Research; Vol 6, Supplement 3 (May 26, 2017): Translational Cancer Research
Y2  - 2017
KW  - 
N2  - The landscape of second line therapy and beyond for advanced non-small-cell lung cancer (NSCLC) continues to evolve. In addition to single agent chemotherapy following a platinum doublet, the use of second line tyrosine kinase inhibitors (TKIs) in patients with targetable molecular mutations, as well as the approval of programmed cell death 1 (PD-1) and programmed death ligands 1 (PDL-1) immunotherapies has greatly expanded the available options, making the clinical choice of a subsequent therapy increasingly complicated.
UR  - https://tcr.amegroups.org/article/view/13579